Do tubular changes in the diabetic kidney affect the susceptibility to acute kidney injury?

Nephron Clinical Practice Pub Date : 2014-01-01 Epub Date: 2014-09-24 DOI:10.1159/000363554
Volker Vallon
{"title":"Do tubular changes in the diabetic kidney affect the susceptibility to acute kidney injury?","authors":"Volker Vallon","doi":"10.1159/000363554","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetes is the single largest contributor to the growing prevalence of chronic kidney disease (CKD), and episodes of acute kidney injury (AKI) increase the risk of advanced CKD in diabetic patients. Here we discuss whether the pathophysiological changes that occur in the tubular system of the diabetic kidney affect the intrinsic susceptibility to AKI. There is abundant data showing that drug-induced nephrotoxicity is attenuated in rodents with experimental diabetes mellitus, and some mechanistic explanations have been provided, in particular in response to aminoglycosides. Besides downregulation in proximal tubular megalin, which mediates the aminoglycoside uptake in proximal tubules, a role for hyperglycemia-induced activation of regenerative mechanisms has been proposed. The available clinical data, however, indicates that diabetes is a risk factor for AKI, including aminoglycoside nephrotoxicity. While much needs to be learned about this disconnect, the isolated induction of diabetes in otherwise healthy young adult rodents may simply not fully mimic the influence that diabetes exerts in the setting of a critically ill and often elderly patient. We speculate that diabetic tubular growth and the associated molecular signature (including upregulation of TGF-β, senescence, and inflammation) set up the development of diabetic nephropathy and renal failure in part by increasing the susceptibility to AKI, which further promotes hypoxia and apoptosis. Considering the strong association between AKI episodes and the cumulative risk of developing advanced CKD in diabetes, strategies that reduce AKI in these patients are expected to help reduce the growing burden of end-stage renal disease.</p>","PeriodicalId":19094,"journal":{"name":"Nephron Clinical Practice","volume":"127 1-4","pages":"133-8"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000363554","citationCount":"29","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephron Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000363554","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/9/24 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 29

Abstract

Diabetes is the single largest contributor to the growing prevalence of chronic kidney disease (CKD), and episodes of acute kidney injury (AKI) increase the risk of advanced CKD in diabetic patients. Here we discuss whether the pathophysiological changes that occur in the tubular system of the diabetic kidney affect the intrinsic susceptibility to AKI. There is abundant data showing that drug-induced nephrotoxicity is attenuated in rodents with experimental diabetes mellitus, and some mechanistic explanations have been provided, in particular in response to aminoglycosides. Besides downregulation in proximal tubular megalin, which mediates the aminoglycoside uptake in proximal tubules, a role for hyperglycemia-induced activation of regenerative mechanisms has been proposed. The available clinical data, however, indicates that diabetes is a risk factor for AKI, including aminoglycoside nephrotoxicity. While much needs to be learned about this disconnect, the isolated induction of diabetes in otherwise healthy young adult rodents may simply not fully mimic the influence that diabetes exerts in the setting of a critically ill and often elderly patient. We speculate that diabetic tubular growth and the associated molecular signature (including upregulation of TGF-β, senescence, and inflammation) set up the development of diabetic nephropathy and renal failure in part by increasing the susceptibility to AKI, which further promotes hypoxia and apoptosis. Considering the strong association between AKI episodes and the cumulative risk of developing advanced CKD in diabetes, strategies that reduce AKI in these patients are expected to help reduce the growing burden of end-stage renal disease.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
糖尿病肾小管改变是否影响急性肾损伤的易感性?
糖尿病是慢性肾脏疾病(CKD)患病率上升的最大因素,急性肾损伤(AKI)的发作增加了糖尿病患者发生晚期CKD的风险。在此,我们讨论糖尿病肾小管系统发生的病理生理变化是否影响AKI的内在易感性。有大量的数据表明,实验性糖尿病啮齿动物的药物性肾毒性减弱,并提供了一些机制解释,特别是对氨基糖苷类的反应。除了在近端小管中介导氨基糖苷摄取的meggalin下调外,已经提出了高血糖诱导的再生机制激活的作用。然而,现有的临床数据表明,糖尿病是AKI的一个危险因素,包括氨基糖苷肾毒性。虽然对这种脱节还有很多需要了解的地方,但在健康的年轻成年啮齿动物中孤立诱导糖尿病可能根本无法完全模仿糖尿病在危重患者和通常是老年患者中施加的影响。我们推测,糖尿病小管生长及其相关的分子特征(包括TGF-β上调、衰老和炎症)通过增加AKI易感性,进一步促进缺氧和细胞凋亡,在一定程度上建立了糖尿病肾病和肾功能衰竭的发展。考虑到AKI发作与糖尿病患者发展为晚期CKD的累积风险之间的强烈关联,减少这些患者AKI的策略有望帮助减轻终末期肾脏疾病日益增长的负担。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Nephron Clinical Practice
Nephron Clinical Practice 医学-泌尿学与肾脏学
自引率
0.00%
发文量
0
审稿时长
6-12 weeks
期刊最新文献
Comparison of Outcomes of In-Centre Haemodialysis Patients between the 1st and 2nd COVID-19 Outbreak in England, Wales, and Northern Ireland: A UK Renal Registry Analysis Association of Serum Triglycerides and Renal Outcomes among 1.6 Million US Veterans Genetic Deletion of the Stromal Cell Marker CD248 (Endosialin) Protects against the Development of Renal Fibrosis Contents Vol. 128, 2014 Author Index Vol. 127, No. 1-4, 2014
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1